Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PACIFIC: pirtobrutinib + short-course immunochemotherapy in untreated CLL
2025-521199-80-00Phase 2Authorised
- Sponsor
- French Innovative Leukemia Organization
- Start
- Nov 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of pirtobrutinib in chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL), sponsored by French Innovative Leukemia Organization. Primary endpoint: Peripheral blood undetectable minimal residual disease at month 24. Planned start Nov 2025; status: authorised.
02
Drugs
pirtobrutinib
03
Conditions
chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL)
Beyond the preview
Go deeper on 2025-521199-80-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-521199-80-00.